Evidence map›Paper›PMID 39041622›Full record

ArticleAIDS research and human retroviruses2024

Knockdowns of CD3zeta Chain in Primary NK Cells Illustrate Modulation of Antibody-Dependent Cellular Cytotoxicity Against Human Immunodeficiency Virus-1.

Sho Sugawara, Esther Lee, Melissa A Craemer, Alayna Pruitt, Harikrishnan Balachandran, Simon B Gressens, Kyle Kroll, Cordelia Manickam, Yuxing Li, Stephanie Jost and 2 more

Abstract read
In one paragraph

Article in AIDS research and human retroviruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sho SugawaraDivision of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, North Carolina, USA.
Esther LeeDivision of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, North Carolina, USA.
Melissa A CraemerDivision of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, North Carolina, USA.
Alayna PruittDivision of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, North Carolina, USA.
Harikrishnan BalachandranDivision of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, North Carolina, USA.
Simon B GressensDivision of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, North Carolina, USA.
Kyle KrollDivision of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, North Carolina, USA.
Cordelia ManickamDivision of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, North Carolina, USA.
Yuxing LiInstitute for Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland, USA.
Stephanie JostDivision of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, North Carolina, USA.
Griffin WoolleyDivision of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, North Carolina, USA.
R Keith ReevesDivision of Innate and Comparative Immunology, Center for Human Systems Immunology, Duke University School of Medicine, Durham, North Carolina, USA.ORCID 0000-0003-3157-2557

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7M
Structure-Function Analytics CoreP01AI162242 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2021 to 2025
$22.2M
High-resolution definition of B cell responses to HIV Env for immunogen designR01AI102766 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI LI, YUXING · 2013 to 2024
$6.6M
Fine Mechanisms of Adaptive NK Cell Formation Against HIV and SIVR01AI161010 · NIAID · DUKE UNIVERSITY · PI JOST, STEPHANIE, REEVES, ROGER KEITH · 2021 to 2025
$4.9M
Next Generation Broadly Neutralizing Antibodies to Clear HIV-1 ReservoirR01AI136756 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LI, QINGSHENG, LI, YUXING · 2019 to 2023
$3.9M
Evolution of anti-filovirus B cell responses and mechanisms of protectionR01AI126587 · NIAID · INTEGRATED BIOTHERAPEUTICS, INC. · PI AMAN, M JAVAD, LI, YUXING · 2017 to 2021
$3.7M
Anti-flavivirus B cell response analysis to aid vaccine designR01AI175439 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Yuxing Li · 2023 to 2026
$3.1M
NIAID NIH HHS P01 AI162242NIAID NIH HHS P30 AI036214NIAID NIH HHS R01 AI102766NIAID NIH HHS R01 AI126587NIAID NIH HHS R01 AI136756NIAID NIH HHS R01 AI161010NIAID NIH HHS R01 AI175439NIAID NIH HHS UM1 AI164570
6 · The paper itself

Abstract

Multifaceted natural killer (NK) cell activities are indispensable for controlling human immunodeficiency virus (HIV)-1 transmission and pathogenesis. Among the diverse functions of NK cells, antibody-dependent cellular cytotoxicity (ADCC) has been shown to predict better HIV-1 protection. ADCC is initiated by the engagement of an Fc γ receptor CD16 with an Fc portion of the antibody, leading to phosphorylation of the CD3 ζ chain (CD3ζ) and Fc receptor γ chain (FcRγ) as well as downstream signaling activation. Though CD3ζ and FcRγ were thought to have overlapping roles in NK cell ADCC, several groups have reported that CD3ζ-mediated signals trigger a more robust ADCC. However, few studies have illustrated the direct contribution of CD3ζ in HIV-1-specific ADCC. To further understand the roles played by CD3ζ in HIV-1-specific ADCC, we developed a CD3ζ knockdown system in primary human NK cells. We observed that HIV-1-specific ADCC was inhibited by CD3ζ perturbation. In summary, we demonstrated that CD3ζ is important for eliciting HIV-1-specific ADCC, and this dynamic can be utilized for NK cell immunotherapeutics against HIV-1 infection and other diseases.

Indexed as

Antibody-Dependent Cell CytotoxicityCD3 ComplexHIV-1Killer Cells, NaturalCells, CulturedGene Knockdown TechniquesHIV AntibodiesHIV InfectionsHumansReceptors, IgGCD3 antigen, zeta chainCD3 ComplexHIV AntibodiesReceptors, IgGcell signalingHIVnatural killer cellSIV

Identifiers

PMID39041622
PMCPMC11631794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.